1. Preoperative detection of the TERT promoter mutations in papillary thyroid carcinomas
- Author
-
Keiji Suzuki, Atsushi Kawakami, Tomoe Nakao, Norisato Mitsutake, Akira Miyauchi, Michiko Matsuse, Tatiana Rogounovitch, Aya Tanaka, Miyoko Higuchi, Mitsuyoshi Hirokawa, Hisanori Sasai, Vladimir Saenko, and Tsutomu Sano
- Subjects
Proto-Oncogene Proteins B-raf ,medicine.medical_specialty ,Mutation ,business.industry ,Endocrinology, Diabetes and Metabolism ,Concordance ,Biopsy, Fine-Needle ,medicine.disease_cause ,Tert promoter ,Thyroid carcinoma ,Endocrinology ,Tumour size ,Thyroid Cancer, Papillary ,Internal medicine ,Cancer research ,Medicine ,Mutational status ,Humans ,Telomerase reverse transcriptase ,Digital polymerase chain reaction ,Thyroid Neoplasms ,business ,Telomerase - Abstract
Telomerase reverse transcriptase promoter (TERT-p) mutations are strongly associated with tumor aggressiveness and worse prognosis in papillary thyroid carcinomas (PTCs). Since the TERT-p promoter mutations have been reported to be subclonal, it is unclear how accurately they can be detected by preoperative fine needle aspiration (FNA). The objective of this study was to analyze the concordance rate of the TERT-p mutations between preoperative FNA and corresponding postoperative surgical specimens. The mutational status of the TERT-p in FNA samples detected by our ddPCR assay was highly concordant with that in postoperative FFPE specimens. The TERT-p mutation was significantly associated with age, tumor size, extrathyroidal extension, and the Ki-67 labeling index in multivariate analysis in both FNA and FFPE samples. The detection of the TERT-p mutations using FNA samples has a good ability to predict disease aggressiveness and, therefore, could be clinically useful in the determination of PTC management.
- Published
- 2021